<DOC>
	<DOCNO>NCT01111526</DOCNO>
	<brief_summary>To test new agent , LBH589 , combination glucocorticoid initial therapy acute graft versus host disease ( GVHD ) .</brief_summary>
	<brief_title>Histone Deacetylase Inhibitor LBH589 Addition Corticosteroids Patients With Acute Graft Versus Host Disease ( GVHD )</brief_title>
	<detailed_description>Dose escalation study test safety ( Phase I ) , pharmacology preliminary clinical activity ( Phase II ) Novel histone deacetylase ( HDAC ) inhibitor , LBH589 , treatment follow GVHD presentation : Classic , Late-onset acute GVHD , Recurrent acute GVHD , Overlap syndrome .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Patients receive allogeneic hematopoietic cell transplantation ( HCT ) peripheral blood , bone marrow cord blood stem cell regardless initial diagnosis develop clinical diagnosis acute GVHD define Section 2 diagnose treat systemic glucocorticoid within 72 hour prior enrollment . Biopsy involve skin gastrointestinal tract strongly encourage , require study entry . For patient aspartic transaminase ( AST ) alanine transaminase ( ALT ) Alkaline phosphatase gammaglutamyltransferase ( GGT ) elevation without bilirubin elevation must liver biopsy document GVHD diagnosis . Patients meet one follow criterion : If GVHD present isolate organ : 1 . Skin rash involvement minimum 50 % body surface area absence document drug allergy infectious etiology . 2 . Diarrhea minimum stool volume 500 mL/day and/or minimum 2 stool baseline/day absence enterocolitis C. difficile document pathogen . 3 . Increase bilirubin upper limit normal ( ULN ) absence clinically define venoocclusive disease . 4 . Isolated increase AST and/or ALT and/or increase alkaline phosphatase ULN GGT elevation ULN document liver GVHD biopsy . If GVHD presentation involve &gt; /= 2 organ : GVHD Grade &gt; /= II define Table D protocol . 2 . Male female patient age 18 old time enrollment 3 . Signed informed consent 4 . Absolute neutrophil count ( ANC ) great 500/Î¼L , platelet &gt; /= 20 x 10^9/L supported platelet transfusion hemoglobin &gt; /= 8 g/dl support red cell transfusion . 5 . Calculated creatinine clearance ( CrCl ) &gt; /= 30 mL/min ( MDRD Formula ) 6 . Serum potassium &gt; /= low limit normal ( LLN ) , Total serum calcium [ correct serum albumin ] ionize calcium &gt; /= LLN , Serum magnesium &gt; /= LLN Serum phosphorus &gt; /= LLN day LBH589 administration 7 . Thyroidstimulating hormone ( TSH ) &lt; /= ULN free T4 within normal limit time patient enrollment within baseline laboratory . Patients permit receive thyroid hormone replacement treat underlie hypothyroidism 8 . Baseline multiple gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) must demonstrate leave ventricular ejection fraction ( LVEF ) &gt; /= low limit institutional normal transplantation . 1 . Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential must negative serum pregnancy test within 24 hr receive first dose study medication pregnancy test do pretransplant . Male patient whose sexual partner WOCBP use effective birth control 2 . Patients require mechanical ventilation support . 3 . Active , uncontrolled life threaten viral fungal disease , cytomegalovirus ( CMV ) pneumonia gastroenteritis , Aspergillus pneumonia brain abscess . For bacterial viral infection , patient must receive therapy sign progression 48 hour prior enrollment . For fungal infection patient must receive systemic antifungal therapy sign progression 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . 4 . Receipt investigational new drug GVHD include agent use GVHD prophylaxis within 30 day . The following agent consider experimental therefore exclude : cyclosporine , tacrolimus , sirolimus , glucocorticoid , antithymocyte globulin , replacement corticosteroid therapy hypoadrenalism methotrexate . 5 . HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer within 30 day . 6 . Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment . 7 . Impaired cardiac function clinically significant cardiac disease , include one following : 1 . Patients congenital long QT syndrome . 2 . History presence sustain ventricular tachyarrhythmia . ( Patients history control atrial arrhythmia eligible ) . 3 . Any history ventricular fibrillation torsade de pointes . 4 . Bradycardia define heart rate ( HR ) &lt; 50 bpm . Patients pacemaker eligible HR &gt; /= 50 bpm . 5 . Patients excluded average QT Corrected Fridericia Formula ( QTcF ) &gt; 470 msec screen EKGs . 6 . Right bundle branch block + leave anterior hemiblock ( bifascicular block ) . 7 . Patients myocardial infarction unstable angina &lt; /= 6 month prior start study drug . 8 . Other clinically significant heart disease ( e.g. , congestive heart failure ( CHF ) New York Heart Association class III IV , uncontrolled hypertension . 8 . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug . 9 . Concomitant use CYP3A4 inhibitor exception tacrolimus , voriconazole ( posaconazole ) , cyclosporine require GVHD patient control GVHD prevent mould infection ( Appendix A protocol ) . 10 . Patients know positivity human immunodeficiency virus ( HIV ) transplant . 11 . Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>allogeneic transplant</keyword>
	<keyword>acute GVHD</keyword>
	<keyword>chronic GVHD</keyword>
</DOC>